Benitec Biopharma Inc.
NASDAQ:BNTCBiotechnology
+$0.36 today
- Market cap
- $288.53M
- Beta
- 0.28
- P/E (TTM)
- -12.3
- EPS (TTM)
- -$0.99
Volume 0.13M
Average 0.11M
BNTC Total Non-current Liabilities
All obligations due after more than one year.
Benitec Biopharma Inc.NASDAQ: BNTC
Total Non-current Liabilities · Q3 FY2026 · quarter ended Mar 2026
Total non-current liabilities falls 35.7% from a year ago
Total non-current liabilities stood at $394K at the end of Q3 FY2026, down 35.7% from a year earlier and down 24.1% from the prior quarter. Over 3 fiscal years it compounded at -4.0% a year.
Context
- Total non-current liabilities amounted to 0.2% of total assets at the end of Q3 FY2026, down 0.4 pp from a year earlier.
- Total non-current liabilities increased in 1 of the last 3 fiscal years.
What to watch
Whether total non-current liabilities keeps falling in the next quarterly balance sheet after a -35.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 495K USD
- Year-over-year change
- +1202.6%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-06-30 | 495K | +1202.6% |
| FY2024 | 2024-06-30 | 38K | -86.6% |
| FY2023 | 2023-06-30 | 284K | -49.2% |
| FY2022 | 2022-06-30 | 559K | — |
| FY2021 | 2021-06-30 | 0 | — |
Total Non-current Liabilities vs competitors
How BNTC compares with its peers on the latest reported figures
- BNTC's Mar 2026 total non-current liabilities of $394K is the lowest of the 10 companies compared; the peer median is $48.69M.
- Its year-over-year change of -35.7% is the 9th highest of 10, against a peer median of +14.9%.
- Total non-current liabilities amounts to 0.2% of total assets for BNTC, versus a peer median of 44.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $354.64M | +14.9% | +32.5% | 67.3% | |
| Dec 2025 | $182.73M | +19.2% | +46.5% | 34.2% | |
| Mar 2026 | $138.69M | +1166.7% | +50.4% | 880.1% | |
| Mar 2026 | $125.89M | +16.9% | +141.1% | 46.3% | |
| Mar 2026 | $48.69M | +131.8% | +20.9% | 44.5% | |
| Mar 2026 | $30.39M | -4.0% | +74.7% | 53.4% | |
| Mar 2026 | $18.48M | -10.6% | -9.9% | 4.4% | |
| Mar 2026 | $6.49M | -31.0% | +22.4% | 2.5% | |
| Mar 2026 | $1.9M | -83.8% | -48.3% | 0.9% | |
| Mar 2026 | $394K | -35.7% | -4.0% | 0.2% | |
| Peer median (excluding BNTC) | $48.69M | +14.9% | +32.5% | 44.5% | |
Competitors are the stored peer set for BNTC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Benitec Biopharma Inc.
NASDAQ:BNTC
Intrinsic Alpha fair value
Locked
Current Price
$8.27
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.